Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Non-Current Deffered Revenue (2021 - 2025)

Autolus Therapeutics' Non-Current Deffered Revenue history spans 5 years, with the latest figure at $253.4 million for Q1 2025.

  • For Q1 2025, Non-Current Deffered Revenue rose 10.92% year-over-year to $253.4 million; the TTM value through Mar 2025 reached $253.4 million, up 10.92%, while the annual FY2024 figure was $244.6 million, 43.13% up from the prior year.
  • Non-Current Deffered Revenue reached $253.4 million in Q1 2025 per AUTL's latest filing, up from $244.6 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $253.4 million in Q1 2025 to a low of $47.0 million in Q4 2021.
  • Average Non-Current Deffered Revenue over 5 years is $151.2 million, with a median of $138.3 million recorded in 2023.
  • Peak YoY movement for Non-Current Deffered Revenue: skyrocketed 168.44% in 2023, then increased 10.92% in 2025.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $47.0 million in 2021, then skyrocketed by 167.78% to $125.9 million in 2022, then surged by 35.74% to $170.9 million in 2023, then skyrocketed by 43.13% to $244.6 million in 2024, then rose by 3.61% to $253.4 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Non-Current Deffered Revenue are $253.4 million (Q1 2025), $244.6 million (Q4 2024), and $248.9 million (Q3 2024).